Completed PHASE1 INTERVENTIONAL 1-arm NCT04984356

A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

A Phase 1 Dose-Escalation and Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Sponsor: National Cancer Institute (NCI)

Conditions Lymphoblastic Lymphoma T-cell Acute Lymphoblastic Leukemia

Interventions WU-CART-007

Updated 20 times since 2021 Last updated: Sep 24, 2025 Started: Jan 14, 2022 Primary completion: Aug 8, 2024 Completion: Aug 8, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Lymphoblastic Lymphoma and T-cell Acute Lymphoblastic Leukemia and is currently completed. National Cancer Institute (NCI) leads this study, which shows 20 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

20 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE1

Phase: PHASE1/PHASE2 → PHASE1
Sep 2025 — Oct 2025 [monthly]

Completed PHASE1/PHASE2
Dec 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Dec 2024 [monthly]

Completed PHASE1/PHASE2

Status: Active Not Recruiting → Completed
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

▶ Show 15 earlier versions

Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1_PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
May 2023 — Aug 2023 [monthly]

Recruiting PHASE1_PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE1_PHASE2
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2
Nov 2022 — Feb 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE1_PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Jul 2022 [monthly]

Recruiting PHASE1_PHASE2
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Oct 2021 — Feb 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Sep 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Wugen, Inc.

Data source: Wugen, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Duarte, United States , Los Angeles, United States , Madison, United States , Melbourne, Australia , Nashville, United States , Paris, France , Philadelphia, United States , Rotterdam, Netherlands , St Louis, United States , Tampa, United States and 1 more location